Algorae Pharmaceuticals Limited, established in 1987 and based in Melbourne, Australia, is a pharmaceutical development company. The firm primarily conducts its research and development in New Zealand, focusing on living cell technologies. Its product pipeline includes several key candidates: AI-116, a novel combination therapy featuring cannabidiol and an existing pharmaceutical ingredient, intended for the treatment of dementia, including Alzheimer's disease; NTCELL, an alginate-coated capsule developed to address Parkinson's disease; and AI-168, another combination drug that combines a cannabinoid with an off-patent pharmaceutical ingredient, aimed at treating cardiovascular conditions like hypertension. Furthermore, in partnership with the University of New South Wales, Algorae is developing AlgaraeOS, an artificial intelligence platform designed to predict biopharmaceutical drug targets, including both fixed-dose combinations and repurposed drugs, without being limited by specific medical indications. The company previously operated as Living Cell Technologies Limited, rebranding to Algorae Pharmaceuticals Limited in September 2023.
—
Algorae Pharmaceuticals Limited, established in 1987 and based in Melbourne, Australia, is a pharmaceutical development company. The firm primarily conducts its research and development in New Zealand, focusing on living cell technologies. Its product pipeline includes several key candidates: AI-116, a novel combination therapy featuring cannabidiol and an existing pharmaceutical ingredient, intended for the treatment of dementia, including Alzheimer's disease; NTCELL, an alginate-coated capsule developed to address Parkinson's disease; and AI-168, another combination drug that combines a cannabinoid with an off-patent pharmaceutical ingredient, aimed at treating cardiovascular conditions like hypertension. Furthermore, in partnership with the University of New South Wales, Algorae is developing AlgaraeOS, an artificial intelligence platform designed to predict biopharmaceutical drug targets, including both fixed-dose combinations and repurposed drugs, without being limited by specific medical indications. The company previously operated as Living Cell Technologies Limited, rebranding to Algorae Pharmaceuticals Limited in September 2023.
—
Daily adjusted close
Algorae Pharmaceuticals Limited, established in 1987 and based in Melbourne, Australia, is a pharmaceutical development company. The firm primarily conducts its research and development in New Zealand, focusing on living cell technologies. Its product pipeline includes several key candidates: AI-116, a novel combination therapy featuring cannabidiol and an existing pharmaceutical ingredient, intended for the treatment of dementia, including Alzheimer's disease; NTCELL, an alginate-coated capsule developed to address Parkinson's disease; and AI-168, another combination drug that combines a cannabinoid with an off-patent pharmaceutical ingredient, aimed at treating cardiovascular conditions like hypertension. Furthermore, in partnership with the University of New South Wales, Algorae is developing AlgaraeOS, an artificial intelligence platform designed to predict biopharmaceutical drug targets, including both fixed-dose combinations and repurposed drugs, without being limited by specific medical indications. The company previously operated as Living Cell Technologies Limited, rebranding to Algorae Pharmaceuticals Limited in September 2023.